May 18, 2016

Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside

Full Text
Posted online on May 10, 2016.
(doi:10.2217/imt-2016-0049)

Chantal Kuhn1 & Howard L Weiner*,1
*Author for correspondence: 
Sections: 


ABSTRACT
Next section
The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.

No comments:

Post a Comment